GLP1R and stroke disorder: Last, but most recently, first GLP-1 receptor agonist CV outcome trial result was published which met the pre-specified criterion of non-inferiority versus placebo for the composite primary endpoint of CV death, non-fatal MI, non-fatal stroke and hospitalization for unstable angina (HR 1.02, 0.89–1.17) [12] (Lixisenatide CV outcome trial was published in December 2015.